The abundant and reversible N6‐methyladenosine (m6A) R
NA
modification and its modulators have important roles in regulating various gene expression and biological processes. Here, we demonstrate that fat mass and obesity associated (
FTO
), as an m6A demethylase, plays a critical anti‐tumorigenic role in clear cell renal cell carcinoma (cc
RCC
).
FTO
is suppressed in cc
RCC
tissue. The low expression of
FTO
in human cc
RCC
correlates with increased tumour severity and poor patient survival. The Von Hippel‐Lindau‐deficient cells expressing
FTO
restores mitochondrial activity, induces oxidative stress and
ROS
production and shows impaired tumour growth, through increasing expression of
PGC
‐1α by reducing m6A levels in its
mRNA
transcripts. Our work demonstrates the functional importance of the m6A methylation and its modulator, and uncovers a critical
FTO
‐
PGC
‐1α axis for developing effective therapeutic strategies in the treatment of cc
RCC
.
Long non-coding RNAs (lncRNAs) are transcripts longer than 200 nucleotides (nts) without obvious protein coding potential. lncRNAs act as multiple roles in biological processes of diseases, especially carcinomas. Prostate cancer associated transcript-1 (PCAT-1) is an oncogenic lncRNA that identified by RNA-Sequence in prostate cancer. High expression of PCAT-1 is observed in different types of cancers, including prostate cancer, colorectal cancer, hepatocellular cancer and gastric cancer. High expressed PCAT-1 is correlated with poor overall survival. Furthermore, PCAT-1 regulates cancer cell proliferation, apoptosis, migration and invasion. Additionally, PCAT-1 is involved in EMT and Wnt/β-catenin-signaling pathway. In this review, we focus on the implication of PCAT-1 in human cancers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.